Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010019099 - 2-HYDROXY-ETHANESULFONATE SALT

Publication Number WO/2010/019099
Publication Date 18.02.2010
International Application No. PCT/SE2009/050926
International Filing Date 11.08.2009
IPC
A61K 31/439 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61P 11/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61K 31/42 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
CPC
A61K 31/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
42Oxazoles
A61K 31/439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61P 1/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants
  • ASTRAZENECA AB [SE]/[SE] (AllExceptUS)
  • PULMAGEN THERAPEUTICS (SYNERGY) LIMITED [GB]/[GB] (AllExceptUS)
  • NADIN, Alan John [GB]/[GB] (UsOnly)
Inventors
  • NADIN, Alan John
Agents
  • ASTRAZENECA AB
Priority Data
0814728.212.08.2008GB
0814729.012.08.2008GB
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) 2-HYDROXY-ETHANESULFONATE SALT
(FR) SEL 2-HYDROXY-ÉTHANESULFONATE
Abstract
(EN) The invention provides (R) -1- [3- (R) -cyclohexyl-hydroxy-phenyl- methyl) -isoxazol-5-ylmethyl] -3- (3-f luoro-phenoxy) -1-azonia- bicyclo[2.2.2]octane 2-hydroxy ethanesulf onate, pharmaceutical compositions containing the compound and its use as a muscarinic antagonists, for the treatment of chronic obstructive pulmonary disease.
(FR) L'invention concerne le 2-hydroxy-éthanesulfonate de (R)-1-[3-(R)-cyclohexyl-hydroxy-phényl-méthyl)-isoxazol-5-ylméthyl]-3- (3-fluoro-phénoxy)-1-azonia-bicyclo[2.2.2]octane, des compositions pharmaceutiques renfermant le composé et son utilisation en tant qu'antagoniste muscarinique, pour le traitement de la bronchopneumopathie chronique obstructive.
Related patent documents
RU2011105465This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau